Industry //

Working with industry

The Maurice Wilkins Centre supports innovation in the biotechnology and drug development sector by providing companies with the expertise and facilities that their research and development programmes require.

Allergan Pharmaceuticals

Allergan, headquartered in Ireland, is a global pharmaceutical company with a focus on developing new medicines in critical therapeutic areas. MWC Investigator Associate Professor Kerry Loomes from the University of Auckland is working with Allergan to develop new therapeutic strategies to combat metabolic disease.

Auckland Clinical Studies Ltd.

This company provides Phase I and II clinical research to local and international pharmaceutical and biotechnology companies. In 2018 Maurice Wilkins Centre investigators Professor Rod Dunbar, Dr Anna Brooks, Dr Dan Verdon and Dr Vaughan Feisst continued to work with Auckland Clinical Studies, providing analytical services such as immune monitoring to support ongoing clinical trials sponsored by a major pharmaceutical company.


Avalia Immunotherapies Ltd.

Avalia Immunotherapies is developing immunotherapies that support the treatment of cancers and other diseases. Investigators Professor Gavin Painter from the Ferrier Research Institute and Professor Ian Hermans from the Malaghan Institute of Medical Research have patented a new immunotherapy technology and are working with Avalia Immunotherapies to further advance the technology and progress it to clinical trials. 


Comvita

Comvita New Zealand is an international natural health products company with offices across Asia, the USA and UK. Comvita are working with investigators Professor Dame Margaret Brimble and Associate Professor Kerry Loomes to identify the active components and biomarkers present in Manuka honey.


Connovation Ltd.

This company is based in Auckland and undertakes research, development and manufacture of invasive animal pest control technologies. The company aims to develop smarter pest control products which are humane, cost effective and more specifically targeted to pest species. Maurice Wilkins Centre investigator Professor Dame Margaret Brimble is working with the company on developing new molecules as humane rodenticides to replace the widely used but controversial pesticide 1080.

 

SapVax LLC.

Sapvax LLC was founded in 2016 and is developing a pipeline of products for the treatment of different cancers, with an initial focus on tumours expressing NY-ESO-1. Professors Dame Margaret Brimble and Rod Dunbar are the academic founders of this company, which is headquartered in the USA, and in 2018 they continued to consult and carry out contract research for the company.